Physician profile
Amy C Tiu
NPI 1841338035
$8,580.28
in general payments reported to CMS, 2019-2025
30 companies · $3,597 in 2025
The $3,597 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.54 · 2021: $101 · 2022: $161 · 2023: $1,186 · 2024: $3,519 · 2025: $3,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,302.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,388.70 | 2022-2025 | Linzess, Creon, Viberzi |
| Janssen Biotech, INC. | $1,382.24 | 2023-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,182.80 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $499.67 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $491.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $460.34 | 2024-2025 | |
| Qol Medical, LLC | $401.21 | 2023-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $379.89 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $338.07 | 2024-2025 | Voquezna |
| Genzyme Corporation | $291.22 | 2024-2025 | |
| Lilly USA, LLC | $270.86 | 2024-2025 | Omvoh, Zepbound |
| Ardelyx, INC. | $206.36 | 2024-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $146.95 | 2023 | Stelara |
| Novo Nordisk INC | $140.63 | 2025 | Wegovy |
| Celgene Corporation | $129.18 | 2023-2024 | Zeposia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $107.39 | 2024 | Xerava |
| Ironwood Pharmaceuticals, INC | $103.49 | 2023-2024 | Linzess |
| Axonics, INC. | $101.22 | 2021 | |
| Intercept Pharmaceuticals, INC. | $98.83 | 2023-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $95.91 | 2023-2024 | Dificid |
| Gilead Sciences, INC. | $72.87 | 2023-2025 | |
| Braintree Laboratories, INC. | $58.86 | 2023-2025 | Suflave |
| Fresenius Kabi USA, LLC | $47.76 | 2023 | Idacio |
| Boston Scientific Corporation | $39.98 | 2024-2025 | Orcapod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.88 | 2023-2024 | Cyltezo |
| Evoke Pharma, INC. | $34.07 | 2023-2024 | Gimoti |
| Alnylam Pharmaceuticals INC. | $25.08 | 2025 | Givlaari |
| Celltrion USA INC. | $17.50 | 2025 | Vegzelma |
| Shionogi INC | $15.54 | 2019 | |
| Azurity Pharmaceuticals, INC. | $13.61 | 2025 | Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Tiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.